tpan.com: Test Positive Aware Network
Home

 


Brand Name: Videx & Videx EC

Common Name: didanosine or ddI

Class:nucleoside analog (also called nucleoside reverse transcriptase inhibitor, NRTI or nuke)

Standard Dose: One 400 mg enteric coated (Videx EC) delayed-release capsule once-a-day, with adjustments for weight and when combined with Viread or Truvada. (Also available in 125 mg, 200 mg and 250 mg caps.) Videx is also available as a buffered powder for oral solution. Take Videx and Videx EC strictly on an empty stomach (unless taking with Viread), one hour before or two hours after food or drink, except water. A reduced dose may be needed for people with kidney problems. Take missed dose as soon as possible, but do not double up on your next dose. Generic Videx EC is available.

AWP: $332.20 for Videx-EC (generic enteric-coated $311.41) / month

Manufacturer contact: Bristol-Myers Squibb,
www.bmsvirology.com, 1 (800) 272–4878

AIDSInfo:1 (800) HIV–0440 (448–0440), www.aidsinfo.nih.gov

Potential side effects and toxicity:

Peripheral neuropathy (tingling, burning, numbness or pain in the hands or feet) may go away once didanosine is stopped, but can be painful and permanently debilitating if not treated in time and occurs more frequently when used with Zerit. Upset stomach, diarrhea, headache, and more rarely pancreatitis has also been reported. Other toxicities include eye changes and optic neuritis. Have periodic eye exam by someone who is aware you are HIV-positive. Increased uric acid levels (indicating a number of disorders, including kidney damage and metabolic diseases), and insomnia are other potential side effects. Rare but potentially fatal toxicity with all NRTIs is pancreatitis, enlarged, fatty liver, and lactic acidosis (accumulation of lactate in the blood and abnormal acid-base balance). Lactic acidosis has been seen in patients taking NRTIs but is more common and more severe in women, people who are obese and people who have been taking nukes for a long time; and more common in people with liver disease, but can occur in people without a history of liver damage. People with lactic acidosis may experience persistent fatigue, abdominal pain or distension, nausea/vomiting, and difficulty breathing or shortness of breath; and enlarged, fatty liver.

People with a history of peripheral neuropathy, pancreatitis or heavy alcohol use should avoid didanosine. Pancreatitis can be life-threatening and may cause pain in the stomach and back, along with nausea, vomiting and blood in the urine. Risks for pancreatitis include: higher than recommended doses of NRTIs, advanced HIV, and alcohol use. Body fat redistribution/accumulation has also been reported with didanosine.

Potential drug interactions:
The levels of didanosine are increased by 44–60% when given at the same time as Viread, therefore a dose reduction to 250 mg for Videx is recommended if you weigh more than 60 kg (132 pounds). See Viread page. The combined use of didanosine and AZT, or hydroxyurea may increase risk of peripheral neuropathy. Combining didanosine with Zerit or with hydroxyurea, alcohol, Cytovene, or intravenous pentamidine (not inhaled) may increase risk of pancreatitis. Combining didanosine with Zerit may increase the risk of lactic acidosis. Also, Cytovene and ribavirin substantially increase didanosine levels, and are generally recommended not to be taken together. Videx should be taken on an empty stomach two hours apart from protease inhibitors, Tagamet, Nizoral, Sporanox and dapsone, and one hour apart from Rescriptor, while Videx EC can be taken with them, but still on an empty stomach. With Viread, it may be taken with a light snack (low-fat, 373 calories). The dose of didanosine may need to be increased when taken with methadone.
Tips:

Study indicates Videx EC (compared to Videx) may have lower risk of peripheral neuropathy. Either drug taken with Zerit increases the risk of facial wasting, pancreatitis, or lactic acidosis. Swallow the capsules whole. The capsules eliminate the bad taste and texture of the tablets and the enteric coating reduces diarrhea. Absorption can be decreased by as much as 50% when taken with food, so take on an empty stomach. Antacids containing magnesium or aluminum may cause adverse side effects if given at the same time as Videx tablets. If you have reduced kidney function, you may require a lower dose. Notify your doctor immediately if peripheral neuropathy is suspected.

Doctor
ddI is much better tolerated in its current enteric coated formation, so patient acceptance is generally good. Use of ddI has diminished due to lack of co-formulations, requirement for use on an empty stomach, enhanced toxicity when used with d4T, very serious (though rare side effects such as peripheral neuropathy and pancreatitis), and relative incompatability with the increasingly used tenofovir (dose adjustment of ddI needed to avoid increased toxicity and concern about blunted CD4 responses). There is less information about use of ddI in contempary regimens pertaining to metabolic and fat effect, so that it is difficult to know where ddI fits in contemporary HIV practice. There has also been difficulty in producing clinically meaningful cut-offs for resistance testing, which is important in order to know where to place ddI in a sequencing strategy. Mistakes to watch for when using ddI include need to dose adjust for body weight and to watch for additive risk for peripheral neuropathy or pancreatitis when used with certain other drugs. Dosing with ribavirin is uncertain, so the drugs should probably not be used together. Use of ddI/d4T in pregnant women is not recommended.—Keith Henry, MD
Activist
Another one of the early HIV medications, ddI (commonly known as Videx) used to be a favorite topic of disdain at support groups. The big chalky pills, which you could either chew (if you could stand it) or dissolve in water (easier, but still tasted like crap) had to be taken separately from your other medications and were frankly a pain in the ass. Eventually the company created a better version of ddI, in the form of Videx-EC. The new enteric-coated capsules were a huge improvement over the pills or powder as far as convenience (due to its once-daily dosing), but unfortunately the side effects associated with Videx (and all the “D” drugs for that matter) still linger. Videx-EC definitely still holds a place in the market for people who may have fewer treatment options available to them, and can be a potent partner in a regimen when paired with the right buddies. It is uncommonly used as a first line therapy in recent years due to the potential side effects and interactions with other drugs, but still might be a good option for someone who can’t use some of the other available nukes for a variety of reasons.—Cathy Olufs
Back to 2007 Drug Guide
Back to Jan/Feb 2007
Back to Positively Aware
 

This site contains HIV prevention messages that may not be appropriate for all audiences. Since HIV infection is spread primarily through sexual practices or by sharing needles, prevention messages and programs may address these topics. If you are not seeking such information or may be offended by such materials, please exit this website.

Este sitio del web contiene mensajes de la prevención del VIH que pueden no ser appropiados para todas las audiencias. Puesto que la infección del VIH es propagada sobre todo con prácticas sexuales o por compartiendo jeringas, los mensajes y los programas de la prevención pueden dirigirse a estos asuntos. Si usted no está buscando tal información o puede ser ofendido por tales materiales, salga por favor de este website.

 
 

Opinions expressed in Positively Aware, Positively Aware en Español, or tpan.com are not necessarily those of staff or membership of Test Positive Aware Network (TPAN), its supporters and sponsors, or distributing agencies. Information, resources, and advertising in Positively Aware, Positively Aware en Español, or tpan.com do not constitute endorsement or recommendation of any medical treatment or product.

TPAN recommends that all medical treatments or products be discussed thoroughly and frankly with a licensed and fully HIV-informed medical practitioner, preferably a personal physician.

Although Positively Aware, Positively Aware en Español, and tpan.com take great care to ensure the accuracy of all the information that it presents, Positively Aware, Positively Aware en Español, and tpan.com staff and volunteers, TPAN, or the institutions and personnel who provide us with information cannot be held responsible for any damages, direct or consequential, that arise from use of this material or due to errors contained herein.

 
 
[an error occurred while processing this directive]
Home   | About TPAN   | Publications   | Client Services   | Events   | Online Directory   | Resources   | Contact Us